8-K
filed October 7, 2025, 7:59 PM ET
ticker ACET
CIK 0001720580
other material
confidence high
sentiment negative
materiality 0.55
Adicet Bio granted 180-day Nasdaq extension; transferred to Capital Market
Adicet Bio, Inc.
- Extension until April 6, 2026 to regain $1.00 minimum bid price; transferred to Nasdaq Capital Market effective Oct 9, 2025.
- Company may consider reverse stock split to meet bid price requirement; if not regained, Nasdaq will issue delisting notice.
- Previous 180-day compliance period ended Oct 6, 2025; extension granted Oct 7, 2025.
- No immediate impact on common stock listing; ACET continues trading under symbol ACET.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-25-233427
- form_type
- 8-K
- ticker
- ACET
- cik
- 0001720580
- company_name
- Adicet Bio, Inc.
- filed_at
- 2025-10-07T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:40.249941+00:00
- generated_at
- 2026-05-17T04:27:55.350542+00:00
- sec_items
- ["3.01", "8.01"]
- event_type
- other_material
- sentiment
- negative
- materiality_score
- 0.55
- calibrated_materiality_score
- 0.55
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-25-233427
- json_url
- https://secwatch.observer/filing/0001193125-25-233427.json
- markdown_url
- https://secwatch.observer/filing/0001193125-25-233427.md
- text_url
- https://secwatch.observer/filing/0001193125-25-233427.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/0001193125-25-233427-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1720580/000119312525233427/acet-20251007.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ISPC
iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance
iSpecimen Inc.
May 13, 2026, 5:00 PM ET
other_material
Items 1.01, 3.01, 3.02, 7.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01
same event type: other_material
similar materiality
This filing
October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o
Comparable filing
minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum
Bid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026
Filing page
SEC filing
TNON
Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity
Tenon Medical, Inc.
May 22, 2026, 5:15 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o
Comparable filing
May 21, 2026, Tenon Medical, Inc. (the “Company”)
received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying
the Company that it is no longer in compliance with the
Filing page
SEC filing
HUMA
Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply
Humacyte, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o
Comparable filing
May 4, 2026, Humacyte, Inc. (the “Company”)
received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification
that, for the 30 consecutive business days ended May 1, 2026, th
Filing page
SEC filing
XXI
Tether International acquires SoftBank's stake in Twenty One Capital; board members resign
Twenty One Capital, Inc.
May 20, 2026, 8:49 AM ET
other_material
Items 1.02, 3.01, 5.02, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01
same event type: other_material
This filing
October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o
Comparable filing
o independent directors, the minimum number required during the transition period
for compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual
Filing page
SEC filing
RVPH
Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB
REVIVA PHARMACEUTICALS HOLDINGS, INC.
May 13, 2026, 8:03 AM ET
other_material
Items 3.01, 8.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01
same event type: other_material
This filing
October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o
Comparable filing
May 12, 2026 indicating that the Panel had determined to delist the Company’s common stock from Nasdaq. The Company’s common stock will be suspended from trading on Nasdaq as of the open of trading on May 14, 2026. Begin
Filing page
SEC filing
GNLN
Greenlane regains Nasdaq compliance; BIC limits warrant conversion; board lock-up to April 2027
Greenlane Holdings, Inc.
April 27, 2026, 7:59 PM ET
other_material
Items 3.01, 7.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01
same event type: other_material
This filing
October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o
Comparable filing
March 25, 2026, Greenlane Holdings, Inc. (the “ Company ”) received a written notice
(the “ Notice ”) from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”)
indicating that Nasdaq s
Filing page
SEC filing
SHFS
SHF Holdings gets Nasdaq deficiency letter; loses court ruling on merger dispute
SHF Holdings, Inc.
April 24, 2026, 7:59 PM ET
other_material
Items 3.01, 5.02, 8.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01
same event type: other_material
This filing
October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o
Comparable filing
April 22, 2026, SHF Holdings, Inc. (the “Company”) received a letter from the listing qualifications department staff of
The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business
Filing page
SEC filing
ADTX
Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11
Aditxt, Inc.
May 29, 2026, 4:21 PM ET
other_material
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
This filing
October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o
Comparable filing
May 27, 2026, Aditxt, Inc. (the “Company”)
received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market
LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s
Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum
stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)
(the “Stockholders’ Equity Requirement”). The Letter further
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.